[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352642-105":59,"doc-detail-352642-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genome-wide-crispr-screens-identify-abcg2-mediated-drug-resistance-to-the-threonine-tyrosine-kinase-ttk-inhibitor-cfi-402257-in-breast-cancer","Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer","","CRISPR screens are a functional genomics strategy for mapping genes that produce sensitivity or resistance to anti-cancer therapies. CFI-402257 (luvixasertib, 2257), a threonine tyrosine kinase (TTK) inhibitor, is pursued for genomically unstable cancers via disruption of the mitotic spindle assembly checkpoint (SAC). CRISPR activation screens in triple-negative breast cancer (TNBC) models identify ABCG2 as the leading resistance gene, with validation showing ABCG2 overexpression increases resistance in vitro while knockdown increases sensitivity. The data suggest 2257 is a substrate of ABCG2 drug efflux, though in vivo TNBC xenografts fail to reproduce resistance under tested dosing. Results stress transporter relevance and the need to validate cell findings in vivo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genome-wide-crispr-screens-identify-abcg2-mediated-drug-resistance-to-the-threonine-tyrosine-kinase-ttk-inhibitor-cfi-402257-in-breast-cancer/352642/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genome-wide-crispr-screens-identify-abcg2-mediated-drug-resistance-to-the-threonine-tyrosine-kinase-ttk-inhibitor-cfi-402257-in-breast-cancer/352642.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the CRISPR activation screens in this study?","Question",{"text":112,"@type":113},"To identify cellular mechanisms that drive resistance to the TTK inhibitor CFI-402257 (2257) in models of triple-negative breast cancer (TNBC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which gene is identified as the top resistance-conferring factor?",{"text":117,"@type":113},"ABCG2 is nominated as the top resistance-conferring gene in two TNBC cell line models.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the in vitro findings relate to in vivo TNBC xenograft results?",{"text":121,"@type":113},"ABCG2 overexpression increases resistance to 2257 in vitro and knockdown increases sensitivity, suggesting ABCG2-mediated drug efflux. However, ABCG2 overexpression does not confer resistance in TNBC xenografts treated with a moderately active dose and schedule.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352642,1790129934,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Article  \nGenome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer  \nKelsie L. Thu 1,2, *, Soode Jafari 3, Jennifer Silvester 3, Jennifer Cruickshank 3, Isabel Soria-Bretones 3, Kelsey Hodgson 3, Chantal Tobin 3, Jillian Haight 3, Asa P. Y. Lau 1,2, Tessa Bray 3, Drew Wakeham 3, Mark R. Bray 3, Tak W. Mak 3,4,5 and David W. Cescon 3,6, *  \nAcademic Editor: Hisham Bahmad  \nReceived: 8 February 2026  \nRevised: 2 March 2026  \nAccepted: 6 March 2026  \nPublished: 14 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto, Toronto, ON M5B 1X3, Canada  \n2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 3K3, Canada  \n3 Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada  \n4 Department of Immunology, University of Toronto, Toronto, ON M5S 3K3, Canada  \n5 Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2C4, Canada  \n6 Institute of Medical Science, University of Toronto, Toronto, ON M5S 3K3, Canada  \n* Correspondence: [kelsie.thu@unityhealth.to](kelsie.thu@unityhealth.to) (K.L.T.); [dave.cescon@uhn.ca](dave.cescon@uhn.ca) (D.W.C.)  \nAbstract  \nCRISPR screens are a powerful functional genomics approach for identifying genes that confer sensitivity and resistance to anti-cancer therapies. CFI-402257 (luvixasertib, 2257) is a small molecule inhibitor of threonine tyrosine kinase (TTK), a promising therapeutic target in genomically unstable cancers due to its critical role in establishing the spindle assembly checkpoint (SAC) during mitosis. To inform its ongoing development and evaluation in clinical trials, we sought to use CRISPR activation (i.e., gain of function) screens to identify cellular mechanisms of resistance to 2257 in models of triple-negative breast cancer (TNBC) . In vitro screens conducted in two TNBC cell lines nominated ABCG2 as the top resistanceconferring gene in both models. Validation studies assessing clonogenic survival and apoptosis confirmed that ABCG2 overexpression enhanced TNBC resistance to 2257 in vitro, while knockdown enhanced sensitivity. These findings suggest that 2257 is a substrate of ABCG2’s drug efflux activity. However, overexpression of ABCG2 failed to confer resistance to 2257 in TNBC xenografts grown in mice and treated with a moderately active dose and schedule. Our results highlight the potential impact of drug transporters in in vitro CRISPR screens and the importance of confirming the relevance of drug response mechanisms identified in cultured cells using in vivo models that recapitulate drug pharmacokineticsand pharmacodynamics.  \nKeywords: CRISPR screen; breast cancer; ABCG2; drug resistance; CFI-402257; luvixasertib  \n1. Introduction  \nThe spindle assembly checkpoint (SAC) is a cell cycle checkpoint that halts mitotic progression until all chromosomes are properly attached to microtubules of the mitotic spindle [1] . Its activation prevents dividing cells from premature progression to anaphase, which can result in severe chromosome segregation errors and aneuploidy in the daughter cells produced. As such, the SAC has a critical role in maintaining genomic integrity. Chromosomal instability (CIN) is a hallmark of cancer cells characterized by a high rate of chromosome missegregation [2,3] . Although CIN creates genetic diversity that fuels tumor  \nevolution and disease progression, it also renders cancer cells hyperdependent on SAC function to survive. As a result, the SAC has emerged as a promising therapeutic target in genomically unstable cancer cells [4,5] . Research in preclinical models has shown that inhibiting kinases that regulate the SAC can","cbCaidEeTueyf8AL","https://ap.wps.com/l/cbCaidEeTueyf8AL","pdf",2705248,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main goal of the CRISPR activation screens in this study?\",\"answer\":\"To identify cellular mechanisms that drive resistance to the TTK inhibitor CFI-402257 (2257) in models of triple-negative breast cancer (TNBC).\"},{\"question\":\"Which gene is identified as the top resistance-conferring factor?\",\"answer\":\"ABCG2 is nominated as the top resistance-conferring gene in two TNBC cell line models.\"},{\"question\":\"How do the in vitro findings relate to in vivo TNBC xenograft results?\",\"answer\":\"ABCG2 overexpression increases resistance to 2257 in vitro and knockdown increases sensitivity, suggesting ABCG2-mediated drug efflux. However, ABCG2 overexpression does not confer resistance in TNBC xenografts treated with a moderately active dose and schedule.\"}]","Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer | PDF",1790100593,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71d5c6b3aae7a8297beff66a9588523e.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/648e5c20ce2e936eb8ef30618a77f45a.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44ba36be2a0ff97b094b4fbcd9f5023c.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10ab91a6f7c42f4153528e0ce8eff730.webp",980,1385]